As Senior Scientist at CYTOO SA since 2010, Joanne Young develops and implements new cell culture models and cell-based screening assays destined for the pharmaceutical and cosmetic industries. Prior to her current position, she performed post-doctoral work in Rainer Pepperkok’s lab at the EMBL-Heidelberg (Germany), at the Curie Institute in Paris (France) and University of Victoria (Canada). Her investigations covered use of aerolysin toxin as a diagnostic tool, the dynamics of vaccinia virus replication factories, dissection of Rab GTPase regulation of protein trafficking pathways and characterization of a novel primate-specific retrogene. Joanne Young received her B.Sc at Manchester University (UK) and Ph.D from the University of Paris XI (France).
Enabling Early Stage Muscle Drug Discovery with MyoScreen™, a High-throughput High-content Phenotypic Screening Platform Deploying Micropatterned Human Primary Skeletal Myotubes
Friday, 25 May 2018 at 11:30
Add to Calendar ▼2018-05-25 11:30:002018-05-25 12:30:00Europe/LondonEnabling Early Stage Muscle Drug Discovery with MyoScreen™, a High-throughput High-content Phenotypic Screening Platform Deploying Micropatterned Human Primary Skeletal MyotubesHigh-Content and Phenotypic Screening Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
CYTOO has recently developed a disease relevant phenotypic muscle drug discovery platform to fully leverage the characterization of compounds at an early stage of the drug discovery pipeline. MyoScreen™ deploys imaging and image-analysis methodology along with a micropatterned plate system that allows the precise control of myotube length and the formation of highly aligned myotubes. In this seminar, I will discuss the robust performance of the MyoScreen™ platform and show how it exploits the improved architecture and maturity of micropatterned myotubes, which are superior to standard 2D culture, to quantitatively analyze drug effects on proliferation, hypertrophy/atrophy, acetylcholine receptors, as well as providing a screening index of contractile force. I will also describe actual use of MyoScreen™ in a primary screen with secondary hit validation, focusing on two intriguing hits that were identified to enhance myotube function by distinct mechanisms of action.
Add to Calendar ▼2018-05-24 00:00:002018-05-25 00:00:00Europe/LondonHigh-Content and Phenotypic Screening Europe 2018High-Content and Phenotypic Screening Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2018-05-25 11:30:002018-05-25 12:30:00Europe/LondonEnabling Early Stage Muscle Drug Discovery with MyoScreen™, a High-throughput High-content Phenotypic Screening Platform Deploying Micropatterned Human Primary Skeletal MyotubesHigh-Content and Phenotypic Screening Europe 2018 in Cambridge, UKCambridge, UKSELECTBIOenquiries@selectbiosciences.com
